Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 1, 1996, Pages 65-69

  Lin, Yue ^a   Leach, William J ^a   Ammons, W Steve ^a  

^a XOMA Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CEFAMANDOLE; CEFAMANDOLE NAFATE; ESCHERICHIA COLI ENDOTOXIN; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SEPSIS;

EID: 0030025638     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.1.65     Document Type: Article

References (46)

1. Ammons, W. S., F. R. Kohn, and A. H. C. Kung. 1994. Protective effects of an N-terminal fragment of bactericidal/permeability increasing protein in rodent models of gram-neaalive sepsis. role of bactericidal properties. J Infect. Dis. 170:1473-1482.
2. Ammons, W. S., and A. H. C. Kung. 1993 A recombinant amino terminal fragment of bactericidal/permeability increasing protein prevents hemodynamic responses to endotoxin. Circ Shock 41:176-184.
3. Bone, R. C. 1993 Gram-negative sepsis a dilemma of modern medicine. Clin Microbiol. Rev. 6:57-68.
4. Burke, D. 1995 Unpublished data
5. Cohen, J., and J. S. McConnell. 1986. Release of endotoxin from bacteria exposed to ciprofloxacin and its prevention with polymyxin B. Eur. J. Clin. Microbiol 5:13-17.
6. Dofferhoff, A. S. M., J. H. Nijland, H. G. de Vries-Hospers, P. O. M. Mulder, J. Weits, and V. J. J. Bom. 1991. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria. an in-vitro and in-vivo study. Scand. J. Infect Dis. 23:745-754.
7. Duma, R. J. 1985. Gram-negative bacillary infections. Pathogenic and pathophysiologic correlates. Am. J. Med. 78:154-164.
8. Fein, A. M., M. Lippmann, H. Holtzman, A. Eliraz, and S. K. Goldberg. 1983. The risk factors, incidence, and prognosis of ARDS following septicemia. Chest 83:40-42.
9. Flynn, P. M., J. L. Shenep, D. C. Stokes, D. Fairclough, and W. K. Hildner. 1987. Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative septicemia. J. Infect Dis 156:706-712.
10. 23, a recombinant fragment of bactencidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect. Immun. 62:1185-1191.
11. Gazzano-Santoro, H., J. B. Parent, L. Grinna, A. Horwitz, T. Parsons, G. Theofan, P. Elsbach, J. Weiss, and P. J. Conlon. 1992. High affinity binding of the bactericidal/permeability increasing protein and a recombinant amino terminal fragment to the lipid A region of lipopolysaccharide. Infect. Immun 60:4754-4761.
12. Gudmundsson, S., and W. A. Craig. 1986. Role of antibiotics in endotoxin shock, p. 238-263. In R. A. Proctor (ed.), Hand book of endotoxin, vol. 4. Clinical aspects of endotoxin shock. Elsevier Science Publisher, Amsterdam
13. Hopkin, D. A. B. 1978. Frapper fort ou frapper doucement. a gram-negative dilemma. Lancet ii:1193-1194.
14. Horwitz, A. H., S. Leigh, S. Abrahamson, H. Gazzano-Santoro, P. Liu, R. E. Williams, S. F. Carroll, and G. Theofan. Expression and characterization of cysteine-modified variants of an amino terminal fragment of bactericidal/ permeability-increasing protein. Submitted for publication
15. 23) inhibits soluble CD14-mediated LPS-induced endothelial adherence for human neutrophils. Shock 1(2):81-86.
16. Kaplan, R. L., S. A. Sahn, and T. L. Petty. 1979. Incidence and outcome of the respiratory distress syndrome in gram-negative sepsis. Arch. Intern. Med. 139:867-869.
17. Kelly, C. J., A. C. Cech, M. Argenteanu, H. Gallagher, J. Shou, E. Minnard, and J. M. Daly. 1993 Role of bactericidal permeability increasing protein in the treatment of gram-negative pneumonia. Surgery 114:140-146.
18. Kohn, F. R., W. S. Ammons, A. Horwitz, L. Grinna, G. Theofan, J. Weickmann, and A, H. C. Kung. 1993. Protective effect of a recombinant amino terminal fragment of bactericidal/permeability increasing protein in experimental endotoxemia J. Infect Dis. 168:1307-1310.
19. Kreger, B. E., D. E. Craven, and W. R. McCabe. 1980 Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am. J. Med. 68:344
20. Kung, A. H. C., W. S. Ammons, Y. Lin, and F. R. Kohn. 1994. Efficacy of a recombinant amino terminal fragment of bactericidal/permeability increasing protein in rodents challenged with LPS or E coli bacteria, p. 255-263 In J. Levin, A. Sturk, T van der Poll, and S. J. H. van Deventer (ed ), Bacterial endotoxin: basic science to anti-sepsis strategies John Wiley & Sons. Inc , New York
21. Lin, Y., F. R. Kohn, A. H. C. Kung, and W. S. Ammons. 1994. Protective effect of a recombinant fragment of bactericidal/permeability increasing piotein against carbohydrate dyshomeostasis and tumor necrosis factor-α elevation in rat endotoxemia. Biochem Pharmacol. 43:1553-1559
22. Lin, Y., W. Leach, S. W. Ammons, and A. H. C. Kung. 1994. Protective effect of a recombinant N-termmal fragment of bactericidal/permeability increasing protein on endotoxic shock in conscious rabbits. Shock 2:324-331.
23. Mandell, G- L., and M. A. Sande. 1985 Antimicrobial agents [continued]: penicillins, cephalosponns, and other beta-lactam antibiotics. p. 1115-1169. In A G Oilman, L. S. Goodman, T. W. Rall, and F Murad (ed.) Goodman and Oilman's the pharmacological basis of therapeutics. Macmillan Publishing Company, New York.
24. Mannion, B. A., J. Weiss, and P. Elsbach. 1990. Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J. Clin. Invest. 85:853-860.
25. Marra, M. N., C. G. Wilde, M. S. Collins, J. L. Snable, M. B. Thornton, and R. W. Scott. 1992. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J. Immunol. 148:532-537.
26. Marra, M. N., C. G. Wilde, J. E. Griffith, J. L. Snable, and R. W. Scott. 1990. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J. Immunol. 144:662-666.
27. Mészáros, K., S. Aberle, R. Dedrick, R. Machovich, A. Horwitz, C. Burr, G. Theofan, and J. B. Parent. 1994. Monocyte tissue factor induction by lipopolysaccharide [LPS]: dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability increasing protein. Blood 83:2516-2525.
28. Mészáros, K., J. B. Parent, H. Gazzano-Santoro, R. Little, A. Horwitz, T. Parsons, G. Theofan, L. Grinna, J. Weicknamm, P. Elsbach, J. Weiss, and P. J. Conlon. 1993. A recombinant amino terminal fragment of bactericidal/ permeability increasing protein inhibits the induction of leukocyte responses by LPS. J. Leukocyte Biol 54:558-563.
29. Ooi, C. E., J. Weiss, M. E. Doerfler, and P. Elsbach. 1991 Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-mcreasing protein of human neutrophils J Exp. Med. 174:649-655.
30. 2-terminal fragment carries all the antibacterial activities of the human neutrophil 60kDa bactericidal/permeability-increasing protein. J Biol. Chem. 262:14891-14894.
31. Parent, J. B. 1995. Unpublished data.
32. Parrillo, J. E. 1989 The cardiovascular pathophysiology of sepsis. Annu. Rev Med. 40:469-485.
33. Prins, J. M., S. J. H. van Derventer, E. J. Kuijper, and P. Speelman. 1994. Clinical relevance of antibiotic-induced endotoxin release Antimicrob. Agents Chemother. 38:1211-1218.
34. Rokke, O., A. Revhaug, B. Osterud, and K. E. Giercksky. 1988. Increased plasma levels of endotoxin and corresponding changes in circulatory performance in a porcine sepsis model: effect of antibiotic administration. Prog. Clin, Biol. Res. 272:247-262.
35. Saladino, R., C. Garcia, C. Thompson, B. Hammer, J. Parsonnet, T. Novitsky, G. Siber, and G. Fleisher. 1994. Efficacy of a recombinant endotoxin neutralizing protein in rabbits with Escherichia coil sepsis. Circ Shock 42: 104-110.
36. SAS institute, Inc. 1990 The GLM procedure. In Sat/stat user's guide, version 6, p. 893-996. SAS Institute, Inc., Cary, N.C.
37. Shenep, J. L., R. P. Barton, and K. A. Morgan. 1985. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gramnegative bacterial sepsis. J. Infect Dis. 151:1012-1018.
38. Shenep, J. L., P. M. Flynn, F. F. Barrett, G. L. Stidham, and D. F. Westenkirchner. 1988. Serial quantitation of endotoxermia and bacteremia during therapy for gram-negative bacterial sepsis J Infect Dis 157:565-568.
39. Shenep, J. L., and K. A. Morgan. 1984. Kinetics of endotoxin release during antibiotic therapy for experimental gram negative bacterial sepsis. J. Infect. Dis 150:380-388.
40. Talan, D. A. 1993 Recent developments in our understanding of sepsis. evaluation of antiendotoxin antibodies and biological response modifiers. Ann. Emerg Med. 22:1872-1890.
41. Tauber, M. G., A. T. Shibl, C. J. Hackbarth, J. W. Larrick, and M. A. Sande. 1987. Antibiotic therapy, endotoxin concentration in cerebrospinal fluid, and brain edema in experimental Escherichia coll meningitis in rabbits. J. Infect Dis. 156:456-462.
42. Tomasz, A. 1986 Penicillin-binding protein and the antibacterial eflectiveness of β-lactam antibiotics. Rev. Infect. Dis. 8(Suppl 3):S260-S278.
43. VanderMeer, T. J., M. J. Menconi, B. P. O'Sullivan, V. A. Larkin, H. Wang, R. L. Kradin, and M. P. Fink. 1994. A recombinant 23-kD fragment of human bactericidal/permeability increasing protein ameliorates acute lung injury and neutrophil activation in porcine endotoxerma I Appl Physiol. 76:2006-2014
44. Weiss, J., P. Elsbach, I. Olsson, and H. Odeberg. 1978. Purification and characterization of a potent bacterial membrane active protein from the granules of human polymorphonuclear leukocytes J. Biol. Chem 253:2644-2672.
45. 2-termina! fragment cause killing of serum-resistant gramnegative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin. Invest 90:1122-1130.
46. Weiss, J., and I. Olsson. 1987. Cellular and subcellular location of the bactericidal/permeability-increasing protein of neutrophils. Blood 69:652-659